Does Bivalent RSV Prefusion F Vaccine prevent RSV-associated lower respiratory tract illness and acute respiratory illness in adults ≥60 years of age?
The bivalent RSVpreF vaccine prevents RSV-associated lower and acute respiratory tract illness in older adults without evident safety concerns.
RSVpreF vaccine prevented RSV-associated lower respiratory tract illness and RSV-associated acute respiratory illness in adults (≥60 years of age), without evident safety concerns. (Funded by Pfizer; RENOIR ClinicalTrials.gov number, NCT05035212; EudraCT number, 2021-003693-31.).
Walsh et al. (Wed,) studied this question.